Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line treatment for metastatic triple-negative breast cancer
2014-000469-35Phase 2Completed
- Sponsor
- Genentech
- Start
- Jun 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in triple-negative breast cancer (TNBC) and breast cancer comparing Ipatasertib + paclitaxel with Placebo + paclitaxel (2 arms). Primary endpoint: Progression-free survival. Started Jun 2014; status: completed.
02
Drugs
ipatasertib
03
Conditions
triple-negative breast cancer (TNBC)breast cancer
Beyond the preview
Go deeper on 2014-000469-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000469-35.